Author

Ingrid A.M. Mandjes

Observed names: I A M Mandjes, I A Mandjes, I Mandjes, I. A. M. Mandjes, I. Mandjes, I.A. Mandjes, I.A.M. Mandjes, IAM Mandjes, INGRID MANDJES, Ingrid A M Mandjes, Ingrid A Mandjes, Ingrid A. M. Mandjes, Ingrid A. Mandjes, Ingrid AM Mandjes, Ingrid Mandjes, Ingrid A.M. Mandjes, Mandjes, I.A.M., Mandjes, Ingrid A

Institution: The Netherlands Cancer Institute

Observed institutions: University College Dublin, Amsterdam UMC Location University of Amsterdam, The Netherlands Cancer Institute, University Medical Center Utrecht, Cancer Research UK Cambridge Center, Medisch Centrum Haaglanden, Reinier de Graaf Hospital, OLVG, Hospital Clínic de Barcelona, Zaans Medisch Centrum, Haga Hospital, Borstkanker Onderzoek Groep, Deventer Ziekenhuis, Vall d'Hebron Institute of Oncology, Stichting Haaglanden Medisch Centrum, Vrije Universiteit Amsterdam, University of Amsterdam

ORCID: 0009-0009-6851-8731

Observed ORCID: 0009-0009-6851-8731

OpenAlex ID: A5111521133

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

2019 · Leonie Voorwerk, Maarten Slagter, et al. · Nature Medicine · 911

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

2018 · Mette S van Ramshorst, Anna van der Voort, et al. · The Lancet Oncology · 459

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

2001 · Jetske M Meerum Terwogt, Wim W ten Bokkel Huinink, et al. · Anti-Cancer Drugs · 278

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2 -Positive Breast Cancer

2021 · Anna van der Voort, Mette S. van Ramshorst, et al. · JAMA Oncology · 158

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

2013 · E. H. Lips, L. Mulder, et al. · Breast Cancer Research and Treatment · 115

PDF

Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.

1990 · M Mannens, P Devilee, et al. · PubMed · 81

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

2024 · Iris Nederlof, Olga I. Isaeva, et al. · Nature Medicine · 80

Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics

2011 · E. H. Lips, L. Mulder, et al. · Breast Cancer Research and Treatment · 80

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

1999 · J M M Terwogt, I A M Mandjes, et al. · British Journal of Cancer · 64

PDF

Toxicity grading systems

1994 · H.R. Franklin, G.P.C. Simonetti, et al. · Annals of Oncology · 62

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

2024 · Anna van der Voort, Fleur M Louis, et al. · The Lancet Oncology · 56

PDF

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy

2009 · S. Rodenhuis, I.A.M. Mandjes, et al. · Annals of Oncology · 54

PDF

High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.

1995 · J B Vermorken, W W ten Bokkel Huinink, et al. · PubMed · 47

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

2023 · Leonie Voorwerk, Olga I. Isaeva, et al. · Nature Cancer · 43

PDF

Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

2018 · Marleen Kok, Leonie Voorwerk, et al. · Journal of Clinical Oncology · 41

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study

2016 · Mette S. van Ramshorst, Erik van Werkhoven, et al. · The Breast · 36

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.

2020 · Anna van der Voort, Mette S. van Ramshorst, et al. · Journal of Clinical Oncology · 34

Autosomal dominant aniridia linked to the chromosome 11p13 markers catalase and D11S151 in a large Dutch family

2008 · M. Mannens, E.M. Bleeker-Wagemakers, et al. · Cytogenetics and Cell Genetics · 33

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

2019 · Leonie Voorwerk, Maarten Slagter, et al. · Nature Medicine · 27

PDF

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

2019 · Richard D. Baird, Annelot G.J. van Rossum, et al. · Clinical Cancer Research · 26

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

2023 · V.C.M. Geurts, L. Voorwerk, et al. · The Breast · 24

PDF

Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial

2017 · M. Kok, H.M. Horlings, et al. · Annals of Oncology · 23

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study

2017 · Mette S. van Ramshorst, Erik van Werkhoven, et al. · European Journal of Cancer · 23

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

2013 · L S Rigter, C E Loo, et al. · British Journal of Cancer · 23

PDF

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

2018 · A.G.J. van Rossum, M. Kok, et al. · European Journal of Cancer · 18

PDF

Works count: 119

Citation count: 2,987

H-index: 23

I10-index: 36